Methods of Clinical Decision-Making | Bleeding & Coagulation Disorders | Vascular Diseases (Non-Coronary) | Acute Cardiovascular Problems
Antiembolic stockings & pneumatic compression in a medical-surgical thromboprophylaxis trial
N Zytaruk*, D Heels-Ansdell, S Vallance, J Marshall, Y Skrobik, DJ Cooper, S Finfer, I Seppelt, M Ostermann, I Qushmaq, M Alsultan, Y Arabi, J Alhashemi, M Al-Hazmi, A Alzem, N Shaikh, Y Mandourah, DJ Cook
*Corresponding author: N Zytaruk
Clinical Epidemiology & Biostatistics, McMaster University, Hamilton, Canada
F1000Posters 2011, 2: 249 (slide presentation) [ENGLISH]
Slide Presentation [1.04 MB]
31st International Symposium on Intensive Care and Emergency Medicine ISICEM 2011, 20 - 23 Mar 2011, P21
A recent randomized trial (CLOTS-1) has called into question the utility of antiembolic stockings (AESs); another trial (CLOTS-2) suggested harm with below knee compared to above knee AESs. AESs and pneumatic compression devices (PCDs) should represent important cointerventions in a heparin thromboprophylaxis trial if exposure was lengthy and frequent. Our objective was to document the use of AESs and PCDs applied per protocol and by protocol violation in a trial comparing UFH vs LMWH in medical-surgical ICU patients (NCT00182143).
3659 patients were recruited internationally. Blinded study drug was administered daily in the ICU. Mechanical prophylaxis was only protocolized for use if anticoagulant prophylaxis was contraindicated (major bleeding, high risk for major bleeding, or suspected or proven heparin-associated thrombocytopenia). Research coordinators prospectively documented daily exposure to study drugs and mechanical prophylaxis.
3659 patients were enrolled for a median (IQR) ICU stay of 9 (5, 16) days. AESs were used per protocol in 17.1% of patients for 1(1, 1) day; 14.1% of the patients had knee length stockings. AESs used in violation of the protocol occurred in only 2.6% of patients (1.9% of the patients had knee length stockings), for which the duration of exposure was 1.5 (1, 4) days. PCDs were used per protocol in 11.1% of patients for 1 (1, 3) days, and in 1.8% of patients for 2 (1, 3) days in violation of protocol.
In keeping with uncertain effectiveness of mechanical thromboprophylaxis, and emerging evidence about harm with knee length stockings, the cointervention of mechanical thromboprophylaxis on the results of PROTECT testing anticoagulant thromboprophylaxis trial will be minimal. AES and PCD use was brief, and largely reserved for days when heparin was contraindicated, as per clinical practice.
No relevant conflicts of interest declared.
McMaster University, NCT00182143
Please note that most posters on this site present work that is preliminary in nature and has not been peer reviewed.
This poster is open access subject to the CC BY-NC Creative Commons 3.0 License